Drug delivery firm Halozyme's Q3 adjusted EPS beats estimates

Halozyme Therapeutics

03/11/2025 21:12

Overview

Halozyme Q3 revenue grows 22% yr/yr, driven by 52% increase in royalty revenue

Adjusted EPS for Q3 beats analyst expectations, showcasing operational efficiency

Company raises 2025 financial guidance, reflecting confidence in continued growth

Outlook

Halozyme raises 2025 revenue guidance to $1,300 - $1,375 mln

Company expects 2025 adjusted EBITDA of $885 - $935 mln

Halozyme projects 2025 non-GAAP EPS of $6.10 - $6.50

Result Drivers

ROYALTY REVENUE - 52% YOY increase driven by ENHANZE-enabled therapies like DARZALEX SC, Phesgo, and VYVGART Hytrulo

NEW INDICATION APPROVALS - DARZALEX SC approved for smoldering multiple myeloma in Europe, VYVDURA in Japan for gMG and CIDP

ELEKTROFI ACQUISITION - Planned acquisition to enhance subcutaneous drug delivery capabilities with high-concentration technology

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
Beat
$1.72
$1.62 (6 Analysts)
Q3 EPS
$1.43
Q3 Net Income
$175 mln
Q3 Operating Income
$217.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Halozyme Therapeutics Inc is $79.00, about 17.5% above its October 31 closing price of $65.19

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nPnBYyVta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)